AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Adenosine 5'-monophosphoramidase HINT2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BX68

UPID:

HINT2_HUMAN

Alternative names:

HINT-3; HIT-17kDa; Histidine triad nucleotide-binding protein 2, mitochondrial; PKCI-1-related HIT protein

Alternative UPACC:

Q9BX68; Q5TCW3

Background:

Adenosine 5'-monophosphoramidase HINT2, also known as HINT-3, HIT-17kDa, and PKCI-1-related HIT protein, is a mitochondrial protein with a pivotal role in hydrolyzing purine nucleotide phosphoramidates. This enzyme specifically targets compounds like adenosine 5'monophosphoramidate (AMP-NH2) and adenosine 5'-O-p-nitrophenylphosphoramidate (AMP-pNA), converting them into AMP and NH2. Its activity extends to the hydrolysis of fluorogenic purine nucleoside tryptamine phosphoramidates in vitro, showcasing its broad substrate specificity.

Therapeutic significance:

Understanding the role of Adenosine 5'-monophosphoramidase HINT2 could open doors to potential therapeutic strategies. Its involvement in crucial biological processes such as steroid biosynthesis and apoptosis highlights its significance in cellular metabolism and survival, presenting a promising target for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.